Connolly Hospital

The trials here

What the 27 trials at this site are about, from their registry records.

Conditions

• Idiopathic pulmonary fibrosis5 trials
• Asthma3 trials
• Obesity3 trials
• Ulcerative colitis3 trials
• COPD2 trials
• Dermatomyositis and polymyositis (myositis)2 trials
• Lupus (SLE)2 trials
• Type 2 diabetes2 trials
• Bronchiectasis1 trial
• Chronic kidney disease1 trial
• Coeliac disease1 trial
• Crohn's disease1 trial
• and 6 more

Phase

• Phase 318 trials
• Phase 28 trials
• Phase 2/31 trial

Status

• Completed12 trials
• Active, not recruiting7 trials
• Recruiting6 trials
• Not yet recruiting2 trials

Lead sponsor

• Boehringer Ingelheim4 trials
• Bristol-Myers Squibb Services Unlimited Company3 trials
• AbbVie2 trials
• Abivax S.A.2 trials
• argenx2 trials
• and 13 more

Running trials

• Recruiting

  A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity

  NCT07843498· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Adult Study Participants With Non-Cystic Fibrosis Bronchiectasis

  NCT07720375· Phase 2· UCB Biopharma SRL· Source

• Recruiting

  A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents with Severe Uncontrolled Asthma (SOLAIRIA-1)

  2025-524040-35-00· Phase 3· Generate Biomedicines Inc.· Source

• Recruiting

  A Study of Efficacy and Safety of Depemokimab Compared With Placebo in Adults and Adolescents With at Risk Type 2 Asthma

  NCT07456033· Phase 3· GlaxoSmithKline· Source

• Recruiting

  AURA-IPF: A Randomized Phase 2 Study to Evaluate the Safety and Efficacy of AP02 (Nintedanib Solution) in IPF

  NCT07194382· Phase 2· Avalyn Pharma Inc.· Source

• Recruiting

  EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease

  NCT07064473· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation

  NCT06959095· Phase 3· GlaxoSmithKline· Source

• Active, not recruiting

  A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab

  NCT06880744· Phase 3· AbbVie· Source

• Active, not recruiting

  WISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF)

  NCT06967805· Phase 2· Mediar Therapeutics· Source

• Active, not recruiting

  A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast

  NCT06238622· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease

  NCT06548542· Phase 2· AbbVie· Source

• Recruiting

  A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis

  2023-503699-25-00· Phase 3· Bristol-Myers Squibb Services Unlimited Company· Source

• Recruiting

  A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Idiopathic Pulmonary Fibrosis

  2023-503697-21-01· Phase 3· Bristol-Myers Squibb Services Unlimited Company· Source

• Enrolling by invitation

  A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy

  NCT05979441· Phase 3· argenx· Source

• Active, not recruiting

  ABTECT - Maintenance

  NCT05535946· Phase 3· Abivax S.A.· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Asthma2 recruiting
• Bronchiectasis1 recruiting
• COPD1 recruiting
• Crohn's disease1 recruiting
• Cystic fibrosis1 recruiting
• High blood pressure1 recruiting
• Idiopathic pulmonary fibrosis1 recruiting
• Obesity1 recruiting
• Type 2 diabetes1 recruiting

Closed trials

• Active, not recruiting

  A Study to Assess the Efficacy and Safety of Verekitug in Participants With COPD

  NCT06981078· Phase 2· Upstream Bio Inc.· Source

• Completed

  A trial to learn how well benralizumab works and how safe it is when given in addition to standard asthma treatments in people with eosinophilic asthma

  2024-515162-13-00· Phase 3· AstraZeneca AB· Source

• Completed

  A Study of the Efficacy and Safety of Efgartigimod in Patients with Primary Sjögren's Syndrome (pSjD) (UNITY)

  NCT06684847· Phase 3· Argenx· Source

• Completed

  A Study of Efficacy, Safety, and Tolerability of KAN-101 in People With Celiac Disease

  NCT06001177· Phase 2· Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SA· Source

• Completed

  A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)

  NCT06077864· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  Efficacy and Safety of Deucravacitinib Compared with Placebo in Participants with Active SLE (POETYK SLE-1)

  2022-500699-76-00· Phase 3· Bristol-Myers Squibb Services Unlimited Company· Source

• Completed

  A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose Weight

  NCT05394519· Phase 3· Novo Nordisk A/S· Source

• Completed

  ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2

  NCT05507216· Phase 3· Abivax S.A.· Source

• Completed

  A Study in People With Systemic Sclerosis to Test Whether Avenciguat (BI 685509) Has an Effect on Lung Function and Other Systemic Sclerosis Symptoms

  NCT05559580· Phase 2· Boehringer Ingelheim· Source

• Completed

  A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy.

  NCT05523167· Phase 2/3· argenx· Source

• Active, not recruiting

  A Study Evaluating the Efficacy and Safety of Afimetoran Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)

  NCT04895696· Phase 2· Beeline Medicines Corporation· Source

• Active, not recruiting

  A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs

  NCT04908202· Phase 3· Bristol-Myers Squibb· Source